Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.
ResMed Inc.'s Chairman and CEO Michael J. Farrell reported an options exercise and stock sale. On January 7, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of ResMed common shares. On the same day, he sold 4,991 ResMed common shares at a weighted average price of $248.4603 per share, in multiple trades between $246.801 and $249.969.
The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Following these transactions, Farrell directly beneficially owned 466,223 ResMed common shares, held in his own name, and indirectly beneficially owned 2,090 shares through the Lisette and Michael Farrell Family Trust. He also held 49,912 ResMed common stock options after the reported exercise; these options first became exercisable on November 11, 2020 and vest one-third per year.
RMD received a Rule 144 notice indicating that shareholder Peter C Farrell plans to sell 2,000 shares of common stock through Merrill Lynch on or about 01/07/2026 on the NYSE. The filing lists an aggregate market value of $497,580 for the planned sale and notes that 44,448,959 shares of the same class were outstanding.
The 2,000 shares to be sold were acquired on 11/11/2014 via a stock option from Peter C Farrell and paid for in cash. Over the past three months, Peter C Farrell previously sold 2,000 shares on 11/12/2025 for gross proceeds of $504,020 and another 2,000 shares on 12/04/2025 for $502,860. By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
Michael Farrell filed a notice to sell 4,991 shares of RMD common stock through Fidelity Brokerage Services LLC on January 7, 2026, with an aggregate market value of $1,240,065.29 on the NYSE.
The shares were acquired the same day via a cash exercise of a stock option originally granted on November 21, 2019. RMD has 145,966,294 common shares outstanding, and over the prior three months Farrell sold 8,009, 8,011, and 4,991 common shares in separate transactions, generating gross proceeds of $2,265,332.03, $2,000,772.95, and $1,254,795.79, respectively.
ResMed Inc.'s Chief Financial Officer reported a small planned share sale. On 01/02/2026, the CFO sold 1,000 shares of ResMed common stock at a price of $241.75 per share in an open market transaction coded as a sale. The filing shows that after this transaction, the officer directly beneficially owns 86,495 shares of ResMed common stock.
The transaction was made under a Rule 10b5-1 trading plan that was adopted on February 19, 2025, indicating it was pre-arranged under SEC rules rather than a discretionary trade at the time of sale.
ResMed Inc.'s Global General Counsel and Secretary reported a small stock sale in a Form 4 filing. On 01/02/2026, the officer sold 50 shares of ResMed common stock at a price of $241.75 per share. After this transaction, the officer beneficially owned 9,741 shares, held directly.
The filing notes that this transaction was conducted under a pre-established Rule 10b5-1 trading plan that was adopted on February 28, 2025. Such plans allow insiders to sell shares according to predetermined instructions, helping separate routine portfolio management from the timing of any company news.
RMD insider Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 241,750.00. The shares are listed on the NYSE, and the approximate sale date indicated is 01/02/2026, with 145,966,294 shares of common stock reported as outstanding.
The 1,000 shares to be sold were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. In the past three months, Sandercock reported selling 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00 and 1,000 common shares on 12/01/2025 for gross proceeds of 244,160.00.
ResMed (RMD) received a notice of proposed stock sales under Rule 144 from an insider. The filer plans to sell 50 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $12,087.50. These shares were acquired on 11/11/2023 through restricted stock vesting from the issuer as compensation. The notice also reports that the same person sold 50 shares of common stock on 12/01/2025 for gross proceeds of $12,208.00 over the past three months.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and share sale. On 12/08/2025, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, converting them into the same number of common shares.
On the same date, he sold 4,991 ResMed common shares at a weighted average price of $251.4117 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed shares, held 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and beneficially owned 54,903 stock options with underlying ResMed shares.
Michael Farrell has filed a notice under Rule 144 indicating a planned sale of 4,991 shares of RMD common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $1,254,795.75. The filing states that 145,966,294 common shares were outstanding at the time of the notice, providing context for the size of this planned sale. The shares to be sold were acquired on 12/08/2025 via an option granted on 11/21/2019 and paid for in cash. The notice also lists prior sales over the past three months, including separate transactions of 8,009, 8,009, and 8,011 common shares, each with disclosed gross proceeds.